The pharmacokinetics of decursin and decursinol angelate (D/DA) were investigated in male SD rats following oral and intravenous administration. D/DA and metabolites obtained from in vitro samples were evaluated by LC/MS. The levels of D/DA and metabolized decursinol in the blood following oral and intravenous administrations declined according to first-order kinetics, with T 1/2 values of 56.67, 58.01, and 57.22 h, respectively, being observed after administration of a dose of 2 mg/kg body weight. The large intestine was the major site of disposition following oral administration. These data indicate that D/DA is rapidly absorbed from the gastrointestinal tract. In in vitro experiment utilizing liver microsomal protein, the major metabolic reaction of D/DA occurred to change decursinol. The cumulative biliary, urinary, and fecal excretions of D/DA in bile duct-cannulated rats was 36.10 ±2.9%, 25.35±3.8%, and 34.20±3.2%, respectively, at 72 h after administration. These results indicate that the absorption of D/DA is almost complete, and that its metabolites are primarily excreted into feces through the bile. These results indicate that D/DA is subject to enterohepatic circulation.
A. gigas Nakai (Cham-Dang-Gui in Korean) is a Korean traditional herbal medicine that is one of the most popular herbal medicines used in Asian countries, including Korea, Japan, and China. A. gigas Nakai is also marketed as a functional food product in Europe and America. A. gigas Nakai from Korea has deep purple flowers, whereas strains from Japan and China have white flowers [2] . A. gigas Nakai has been studied extensively and found to contain a variety of substances including coumarins [3, 11] . Coumarins are composed of D/DA, which has long been used as a traditional medicine for the treatment of anemia, as a sedative, and as an anodyne or a tonic agent [13] . In addition, A. gigas Nakai has been widely used for the treatment of dysmenorrhea, amenorrhea, menopause, abdominal pain, injuries, migraine headaches, and arthritis. Furthermore, A. gigas Nakai is known to exert antibacterial and antiamnestic effects, as well as to induce inhibitory effects against acetylcholinesterase, depression of cardiac contraction, and activation of protein kinase C [1, 4, 6, 7, 12] . Many herbal medicines are used in functional food products; however, there is currently a great deal of concern over possible genetic hazards associated with such medicines [5] . Additionally, methods for improving the storage conditions and quality of herbal medicines have recently been evaluated.
The primary objectives of the present study were to determine the absorption, tissue distribution, metabolism, and elimination of D/DA following oral or intravenous (IV) administration to male Sprague-Dawley rats. Additional studies involving jugular vein cannulation were conducted to determine the bioavailability of D/DA following oral administration. Finally, studies using bile duct-cannulated rats were conducted to investigate the metabolism of D/DA as well as its biliary elimination following oral administration.
MATERIALS AND METHODS
Chemicals D/DA was extracted from A. gigas Nakai with 60% ethanol and determined to have a purity of 95% by HPLC (data not shown). Acetonitrile, methanol, and other reagents were purchased from Sigma (St. Louis, MO, U.S.A.).
Animals and Dosage Forms
Male Sprague-Dawley rats (240±10 g) were used in this study (Samtako, Osan, Korea). The animals were allowed free access to *Corresponding author Phone: +82-51-663-4882; Fax: +82-51-663-4809; E-mail: jskang8551002@kyungsung.ac.kr food and water, but were fasted overnight prior to treatment. Animals were kept in a temperature-controlled environment (23±2 o C) with a 12 h light-dark cycle and a relative humidity of 50±10%. It was found that 2 mg/kg of D/DA would be effective to improve the streptozotocin-induced diabetic rats and the gout of rats, in former experiments (data not shown). For oral administration, D/DA was dissolved or suspended in 1% DMSO at a concentration of 200 mg/kg body weight. For intravenous administration, D/DA was dissolved in 1% DMSO at a concentration of 2 mg/kg (1 ml/min) body weight.
HPLC/MS Analysis
The optimal conditions of D/DA detection were achieved using an HPLC (Agilent Technologies, 1100 series; U.S.A.) column (Agilent Zorbax SB-C18, 250 mm×4.6 mm, 5 µm) and detection at 329 nm using a UV monitor (Agilent Technologies, 1100 series, PhotoDiode Array UV/Vis detector; U.S.A.). The column was held at room temperature and the mobile phase consisted of 70:30 (v/v %) acetonitrile and 0.1% formic acid for absorption, distribution, and excretion. In vitro metabolism was analyzed by the gradient method with the mobile phase consisting of acetonitrile and 0.1% formic acid. Chromatography was performed isocratically at a flow rate of 1 ml/min using the same mobile phase described above. Next, ESI/ MS analysis was performed on an Agilent Technologies G2708DA electrospray mass spectrometer equipped with an Agilent Technologies Atmospheric Pressure Ionization (API) interface fitted with a hexapole ion guide. The optimal conditions for the analysis of D/DA included pneumatic nebulization with nitrogen (45 psi.) and a counter flow of nitrogen (12 l/min) heated to 350 o C for nebulization and desolvation of the introduced liquid.
Liver Microsomal Incubation and In Vitro Metabolism
The rats were sacrificed by cervical dislocation. Preparation of the liver microsomes and biotransformation were performed as described previously [9] . The extra blood from the livers was perfused with saline to remove the blood and then homogenized with four volumes of ice-cold 0.1 M potassium phosphate buffer (pH 7.4). The liver homogenates were then centrifuged at 8,700 rpm for 10 min at 4 o C. The supernatants were centrifuged again at 27,000 rpm for 60 min at 4 o C. The microsomal pellets were resuspended in 0.1 M potassium phosphate buffer (pH 7.4) containing 20% glycerol. Aliquots of liver microsomes were stored at -80 o C until used. The liver microsomes were analyzed as described previously using bovine serum albumin as a standard [10] . The metabolism of D/DA (100 µM) was determined by incubating the samples with 1 mg/ml microsomal protein in 0.1 M phosphate buffer (pH 7.4) at 37 o C for 120 min in a reaction mix with a final volume of 500 µl. The reaction was initiated by the addition of NADPH (0.8 mM, final concentration), 10 mM glucose 6-phosphate, and 1 unit of glucose-6-phosphate dehydrogenase to the reaction mixture. The reaction was terminated by the addition of 1 ml of ethyl acetate. After mixing and centrifugation, 500 µl of the organic layer was separated. The organic layer was then dried under a stream of nitrogen gas and analyzed by HPLC/MS. 
Tissue and Organ Distribution
Four rats were anesthetized with ether and then exsanguinated from the descending aorta using a heparinized disposable plastic syringe at 40 min after oral administration of D/DA. The procedure was conducted at 40 min, because that is when the highest concentration of D/DA in the plasma was observed after oral administration. Twelve major tissues and organs were then sampled by dissection. The organs were blot-dried with paper, and the total weight of each of the tissues and organs was then measured. Next, tissue samples of each organ were homogenized with 3 volumes of 10 mM potassium phosphate buffer solution using a Powergen homogenizer (Fisher Co., U.S.A.). The samples were then centrifuged and the supernatant was stored at -70 o C until HPLC analysis.
Urinary, Fecal, and Biliary Excretions
Urine, feces, and bile samples were collected at 0, 1, 3, 5, 8, 10, 24, 36, 48, and 72 h after administration of D/DA at a dose of 200 mg/kg body weight to bile duct-cannulated rats using a metabolic cage (Nalgene Co., U.S.A.). For analysis, 0.3 ml of bile and 1 ml of urine were extracted in 3 ml of ethyl acetate, after which 1 ml of the organic phase was subjected to vacuum evaporation. The residue was then reconstituted with 50 µl of the mobile phase. The feces samples were homogenized in 3-fold distilled water using a Powergen homogenizer, after which the samples were subjected to the same treatment as the urine and bile. All samples were stored at -70 o C until HPLC analysis.
RESULTS AND DISCUSSION

In Vitro Metabolism Study
The in vitro characteristics of D/DA after incubation with the liver microsomes of rats are shown in Fig. 1 . The compound was more hydrophilic than D/DA, with a retention time of 13.162 min (Fig. 1) . The parent and primary metabolite were detected after microsomal incubation of D/DA. HPLC/MS revealed the presence of one major peak 
Pharmacokinetics
The plasma concentration-versus-time profiles of D/DA and metabolized decursinol following oral and intravenous administrations of 200 and 2 mg/kg of the compound to Sprague-Dawley rats are shown in Fig. 2 and 3 . Pharmacokinetic parameters, such as the maximum time (t max , h), maximum concentration (C max , µg equiv. of D/ DA/ml), elimination half-lives (t 1/2 , h), and AUC 36-108 (area under the blood concentration-time curve from 36 to 108 h) derived from the plasma curve analysis are shown in Table 1 . After administration of a single oral dose of D/DA, the concentrations of D/DA and metabolized decursinol in the plasma reached maxima of 1,278.26, 592.16, and 186.75 µg/ml in male rats at 1, 1.3, and 1 h after oral administration, respectively. Thereafter, the concentration of D/DA in the plasma declined and approached the limit of quantification, 72 and 108 h after oral and intravenous administration, respectively. The elimination half-lives (t 1/2 , h) of D/DA and decursinol in the plasma for male rats after intravenous administration were estimated to be 56.67, 58.01, and 57.22 h, respectively, using first-order kinetics. Based on the ratio of AUC PO to AUC IV in the plasma, the absorption rate of D/DA in male rats was estimated to be >95%. These results indicate that most of the D/DA and metabolized decursinol administered was absorbed from the gastrointestinal tract, after which it was eliminated from the body. These findings indicate that D/DA is poorly and slowly absorbed across the gut and via the blood following oral and intravenous administrations. In addition, the oral and intravenous administration data demonstrated that D/DA is readily extracted during systemic circulation by the plasma. This slow absorption results in extensive excretion in the feces. These results indicate that D/DA shows promise for use as an antitumor agent owing to its long half-life in the plasma [8] .
Distribution Study
The distribution of D/DA in the tissues and organs after administration of a single oral dose of 200 mg/kg is shown in Table 2 . D/DA was rapidly distributed to all of the tissues and organs within 40 min of administration. As shown in Table 2 , these high concentrations in the excretory and metabolizing organs indicate that excretion and metabolism began immediately after absorption. Based on the concentrations of D/DA in the tissues and organs in male rats, it is expected that D/DA is slowly eliminated from tissue organs in rats in a manner similar to its elimination from plasma.
Excretion Study
Following oral administration, the cumulative excretion of D/DA via urine, feces, and bile was examined for 72 h using metabolic cages. The urinary, biliary, and fecal excretion data from the bile duct-cannulated rats are shown in Fig. 4 . When D/DA was administered orally, >90% of the administered dose was excreted 2 days after administration. The cumulative excretions of D/DA in the urine, feces, and bile for 72 h after administration accounted for 25.35± 3.8%, 34.20±3.2%, and 36.10±2.9%, respectively. These findings indicate that 95.65±0.46% of the total dose of D/ DA administered was excreted within 72 h.
In conclusion, these data show that D/DA was slowly absorbed across the gut lumen following oral and intravenous administrations. These data also indicate that, following oral and intravenous administrations, greater than 90% of D/DA was absorbed and metabolized. There was no notable accumulation of D/DA in the whole blood or tissues.
